NCT07211542

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

A Randomized, Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of SHR-1905 Injection in Patients With Moderate to Severe Atopic Dermatitis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (estimated)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.

Conditions

• Moderate-to-severe Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	SHR-1905 Injection	SHR-1905 injection.
DRUG	SHR-1905 Injection Blank Preparation	SHR-1905 injection blank preparation.

Timeline

• Start date: 2025-11-07
• Primary completion: 2026-09-01
• Completion: 2027-02-01
• First posted: 2025-10-08
• Last updated: 2026-04-08

Locations

1 site across 1 country: China